Please login to the form below

Not currently logged in
Email:
Password:

Amgen bone drug cleared for cancer use

Amgen has won US FDA approval of osteoporosis drug denosumab for use in patients with bone metastases from solid tumours

Amgen has won US Food and Drug Administration (FDA) approval of its marketed osteoporosis drug denosumab for the new indication of preventing skeletal-related events (SRE) in patients with bone metastases from solid tumours. The drug, which is sold under the tradename Prolia for osteoporosis, will be known as Xgeva for the oncology indication.

The new approval was based on the FDA's six-month priority review of Amgen's marketing application, which included data in more than 50 tumour types in about 5,700 patients.

Results of three phase III trials comparing Xgeva to Novartis' Zometa (zoledronic acid) found that Xgeva was more effective for reducing SREs in patients with breast or prostate cancer and bone metastases. The two drugs had similar efficacy in patients with bone metastasis due to other solid tumours or bone lesions due to multiple myeloma, and the overall rates of adverse events were similar between the two.

Xgeva has the advantage of being administered as a once-monthly subcutaneous injection, whereas Zometa is an intravenous infusion given every three to four weeks.  In addition, unlike Zometa, the Amgen drug does not require dose adjustment for changes in renal function.

Bone metastases, the spread of cancer to the bones, affect as many as 75 per cent of patients with advanced prostate, lung, and breast cancer. The cancer can weaken bones, leading to SREs such as fractures and compression of the spinal cord. Xgeva is a fully human monoclonal antibody that works by inhibiting the RANK Ligand pathway, which was indentified over a decade ago by Amgen scientists as playing a central role in cancer-induced bone destruction.

Amgen will try to lessen the financial impact of the very expensive drug on patients through its Xgeva First Step Coupon Programme, a commercial co-pay programme with no income eligibility requirement. The programme is designed for patients who have insurance but need help meeting their deductible, co-insurance, and/or co-payment requirements. Eligible patients will receive their first injection for free and will pay no more than $25 out-of-pocket for each subsequent injection, according to the company.

Marketing applications for Xgeva are pending in the European Union, Australia, Canada and Switzerland, as well as in Japan, where Amgen has licensed the product to Daiichi-Sankyo.

19th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics